Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL2 | P60568 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 3/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | RORB | Q92753 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5049013 | 0.90 | IL2 (0.54) | IL2KMT2AMEN1ALDH1A1TRPA1 | |
| SCHEMBL5049766 | 0.89 | IL2 (0.57) | IL2KMT2AMEN1ALDH1A1TRPA1 | |
| SCHEMBL5049909 | 0.88 | IL2 (0.58) | IL2KMT2AMEN1ALDH1A1TRPA1 | |
| SCHEMBL5051440 | 0.87 | IL2 (0.55) | IL2KMT2AMEN1ALDH1A1TRPA1 | |
| SCHEMBL5049038 | 0.87 | IL2 (0.55) | IL2KMT2AMEN1ALDH1A1TRPA1 | |
| SCHEMBL8239205 | 0.87 | IL2 (0.57) | IL2KMT2AMEN1ALDH1A1TRPA1 | |
| SCHEMBL5245746 | 0.87 | IL2 (0.57) | IL2KMT2AMEN1ALDH1A1GAA | |
| SCHEMBL15702700 | 0.87 | MEN1 (0.53) | IL2KMT2AMEN1ALDH1A1TRPA1 | |
| SCHEMBL5052516 | 0.86 | IL2 (0.56) | IL2KMT2AMEN1ALDH1A1TRPA1 | |
| SCHEMBL15702703 | 0.85 | IL2 (0.51) | IL2KMT2AMEN1ALDH1A1TRPA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140135331-A9 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-05-15 | — | — | US | claimed |
| US-20130317032-A1 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-11-28 | — | — | US | claimed |
| EP-1983980-A2 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2008-10-29 | — | — | EP | claimed |
| US-20070254925-A1 | Thiazole and thiadiazole compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-01 | — | — | US | claimed |
| WO-2007087427-A2 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-02 | — | — | WO | claimed |
| US-20140135331-A9 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20140135331-A9 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-05-15 | — | — | US | disclosed |
| US-20130317032-A1 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2013-11-28 | — | — | US | disclosed |
| US-8455658-B2 | Thiazole and thiadiazole compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455658-B2 | Thiazole and thiadiazole compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8455658-B2 | Thiazole and thiadiazole compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| EP-1983980-A2 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2008-10-29 | — | — | EP | disclosed |
| US-20070254925-A1 | Thiazole and thiadiazole compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254925-A1 | Thiazole and thiadiazole compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254925-A1 | Thiazole and thiadiazole compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-11-01 | — | — | US | disclosed |
| WO-2007087427-A2 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-02 | — | — | WO | disclosed |
| WO-2007087427-A2 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130317032-A1 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCR1, NLRP3, NLRP1 | IL2 29/4885KMT2A 4375/4885MEN1 3972/4885 |
| US-20140135331-A9 | THIAZOLE AND THIADIAZOLE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCR1, NLRP3, NLRP1 | IL2 29/4885KMT2A 4375/4885MEN1 3972/4885 |
| US-20070254925-A1 | Thiazole and thiadiazole compounds for inflammation and immune-related uses | CXCR1, NLRP3, NLRP1 | IL2 29/4885KMT2A 4375/4885MEN1 3972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.